Danuta J. Herzyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danuta J. Herzyk has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Peter J. Bugelski
Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA, Presently at J&J/Centocor, Inc., Malvern, Pennsylvania, USA
3 shared publicationsCurtis C. Maier
Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
2 shared publicationsElizabeth R. Gore
Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
2 shared publicationsJeanne M. Soos
Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
2 shared publicationsKimberly L. Nadwodny
Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
2 shared publicationsPadma K. Narayanan
Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
2 shared publications
Latest Publications
- 17 May 2005
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 19 (3) , 323-328
Assessing immunotoxicity of pharmaceuticals: the need for enhanced testing
- 17 May 2005
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 19 (3) , 323-328
Assessing immunotoxicity of pharmaceuticals: the need for enhanced testing
- 1 April 2004
- Published by Elsevier in Toxicology Letters
- Vol. 149 (1-3) , 115-122
Adequate immunotoxicity testing in drug development
- 1 April 2004
- Published by Elsevier in Toxicology Letters
- Vol. 149 (1-3) , 115-122
Adequate immunotoxicity testing in drug development
- Open Access
- 1 August 2003
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 31 (5) , 554-561
Preclinical Safety of Recombinant Human Interleukin-18
Recombinant human interleukin-18 (rHuIL-18) is currently in clinical trials for treatment of cancer. This report presents results of preclinical toxicity studies with rHuIL-18 in cynomolgus monkeys and recombinant murine IL-18 (rMuIL-18) in mice. The rHuIL-18 was administered intravenously in 1 or 2 different 5-day cycles at doses 0.3 to 75 mg/kg/day in monkeys. Decreases in red cell mass, neutrophil, and platelet counts, increases in monocyte and large unstained cell counts, and lymphoid hyperplasia in spleen and lymph nodes were mild, reversible, and likely related to the pharmacologic activity of IL-18. The only toxic effect was protein cast nephropathy, secondary to coprecipitation of administered IL-18 and Tamm-Horsfall protein in the distal nephron, that only occurred at 75 mg/kg/day. Other adverse effects of rHuIL-18 were related to strong immunogenicity in monkeys and were manifest only during a second dosing cycle. The rMuIL-18, at similar dosing levels and cycles in mice, resulted in reduced red cell mass, increased white blood cell counts, spleen and lymph node hyperplasia, and mild, reversible changes in intestine, liver, and lungs. Protein cast nephropathy occurred in mice at doses ≥30 mg/kg/day. In conclusion, preclinical safety studies showed that rIL-18 was well tolerated at pharmacologically active doses in both monkeys and mice.
- 1 August 2003
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 31 (5) , 554-561
Open AccessPreclinical Safety of Recombinant Human Interleukin-18
Recombinant human interleukin-18 (rHuIL-18) is currently in clinical trials for treatment of cancer. This report presents results of preclinical toxicity studies with rHuIL-18 in cynomolgus monkeys and recombinant murine IL-18 (rMuIL-18) in mice. The rHuIL-18 was administered intravenously in 1 or 2 different 5-day cycles at doses 0.3 to 75 mg/kg/day in monkeys. Decreases in red cell mass, neutrophil, and platelet counts, increases in monocyte and large unstained cell counts, and lymphoid hyperplasia in spleen and lymph nodes were mild, reversible, and likely related to the pharmacologic activity of IL-18. The only toxic effect was protein cast nephropathy, secondary to coprecipitation of administered IL-18 and Tamm-Horsfall protein in the distal nephron, that only occurred at 75 mg/kg/day. Other adverse effects of rHuIL-18 were related to strong immunogenicity in monkeys and were manifest only during a second dosing cycle. The rMuIL-18, at similar dosing levels and cycles in mice, resulted in reduced red cell mass, increased white blood cell counts, spleen and lymph node hyperplasia, and mild, reversible changes in intestine, liver, and lungs. Protein cast nephropathy occurred in mice at doses ≥30 mg/kg/day. In conclusion, preclinical safety studies showed that rIL-18 was well tolerated at pharmacologically active doses in both monkeys and mice.
- 1 April 2003
- Vol. 5 (2) , 167-71
The immunogenicity of therapeutic cytokines.
Therapeutic cytokines that modulate immune responses are designed to enhance host defense to combat tumors and chronic infections. In general, cytokines are pleiotropic molecules and mediate both systemic and local immune activities. Therapeutic recombinant human cytokines currently in clinical use include interferons (IFN alpha, IFN beta and IFN gamma), interleukins (IL-2 and IL-12) and hematopoietic factors such as granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, erythropoietin and thrombopoietin. Their use as therapeutic agents has been challenging since the safety and efficacy of these products are complicated by immunogenicity issues.
- 1 April 2003
- Vol. 5 (2) , 167-71
The immunogenicity of therapeutic cytokines.
Therapeutic cytokines that modulate immune responses are designed to enhance host defense to combat tumors and chronic infections. In general, cytokines are pleiotropic molecules and mediate both systemic and local immune activities. Therapeutic recombinant human cytokines currently in clinical use include interferons (IFN alpha, IFN beta and IFN gamma), interleukins (IL-2 and IL-12) and hematopoietic factors such as granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, erythropoietin and thrombopoietin. Their use as therapeutic agents has been challenging since the safety and efficacy of these products are complicated by immunogenicity issues.
- 1 September 2002
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 21 (9-10) , 507-512
Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero
Keliximab is a human-cynomolgus monkey chimeric (Primatized) monoclonal antibody with specificity for human and chimpanzee CD4. As the preclinical safety assessment of biopharmaceuticals requires evaluation in pharmacologically responsive species, comprehensive toxicology studies, including reproductive toxicity, of this antibody were conducted in a human CD4 transgenic mouse model. The reproductive toxicology studies included a preand postnatal development study that incorporated immunotoxicological evaluation of offspring (F1) mice. The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. The results showed no impairment of these functions. The use of F1 transgenic mice in study with keliximab provides an example of a novel practical approach to assess developmental immunotoxicity within a study of preand postnatal development designed in accordance with ICH Guidelines.
- 1 September 2002
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 21 (9-10) , 507-512
Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero
Keliximab is a human-cynomolgus monkey chimeric (Primatized) monoclonal antibody with specificity for human and chimpanzee CD4. As the preclinical safety assessment of biopharmaceuticals requires evaluation in pharmacologically responsive species, comprehensive toxicology studies, including reproductive toxicity, of this antibody were conducted in a human CD4 transgenic mouse model. The reproductive toxicology studies included a preand postnatal development study that incorporated immunotoxicological evaluation of offspring (F1) mice. The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. The results showed no impairment of these functions. The use of F1 transgenic mice in study with keliximab provides an example of a novel practical approach to assess developmental immunotoxicity within a study of preand postnatal development designed in accordance with ICH Guidelines.